{
  "docId": "019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "docSlug": "2cfade3d34acc49c8d5f05063b654956",
  "documentTitle": "ATAI | Investor Presentation Deck | 49 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 49,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "other",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a three-column layout to detail specific biotech subsidiaries/partnerships.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-19a4-704e-b5bc-b8f4ae0c7550/34",
  "deckHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "deckJsonHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550.json",
  "deckAnchorHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "diagram",
      "text": "Biomarker stratification focused vs Platform companies dedicated towards advancements in formulation",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2577fa00-1962-4336-b653-820214ffcdc8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.67,
        "y": 0.28
      },
      "kind": "list",
      "text": "IntelGenx: An OTF manufacturer in Canada... Strategic partnership with a minority ownership of 25%... IntelGenx is developing an OTF formulation of Viridia's VLS-01... Oromucosal absorption avoids the stomach...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa59d22e-9d69-4ec4-9eed-ae08b1ce3e74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.36,
        "y": 0.28
      },
      "kind": "list",
      "text": "InnarisBio: Dedicated to developing a sol-gel based, intranasal excipient technology... Joint venture with UniQuest... InnarisBio uses a non-invasive, nose-to-brain delivery technology... Potential advantages include increased patient compliance...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cde3fa15-cb07-4b70-9841-a330f86f7369",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "PsyProtix: Developing metabolomics-based biomarkers that stratify TRD patients... Joint venture with Chymia LLC... Focusing on metabolomic mechanisms... Targeting treatments to allow physicians to prescribe treatments specifically targeted...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5e00773-7434-4cf3-8bb0-07b19ec4c913",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "(1) PsyProtix will serve as both a discovery stage company targeting TRD with mitochondrial dysfunction AND as a metabolomics biomarker platform with broader applicability",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "415a5117-56d6-4841-aefc-4e00d61fd1d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Our formulation & biomarker stratification companies provide an additional avenue of growth & innovation to the atai platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bbaa5f8a-6924-4f40-8c52-179805e140fa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "16811dab-f858-4843-aeb4-6a7162ec9117",
      "evidence": "The slide contains a list/bullet with several points.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}